Patent SG-11201900379R-A (SG)
Title: 9-aminomethyl minocycline compounds and uses thereof
Inventor: TANAKA S
IPC: C07C237/26
Filed: 2017-08-03
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 01110101111101M0 IIMI0 ill OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/026987 Al 08 February 2018 (08.02.2018) W I P0 I P C T (51) International Patent Classification: Declarations under Rule 4.17: A61K 31/65 (2006.01) CO 7C 237/26 (2006.01) A61P 31/04 (2006.01) — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) (21) International Application Number: — as to the applicant's entitlement to claim the priority of the PCT/US2017/045220 earlier application (Rule 4.17(iii)) (22) International Filing Date: Published: 03 August 2017 (03.08.2017) — with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/370,527 03 August 2016 (03.08.2016) US 62/514,479 02 June 2017 (02.06.2017) US 62/532,454 14 July 2017 (14.07.2017) US (71) Applicant: PARATEK PHARMACEUTICALS, INC. [US/US]; 75 Park Plaza, 4th Floor, Boston, MA 02116 (US). (72) Inventors: TANAKA, S., Ken; 10030 SE 6th Street, Apt. 201, Bellevue, WA 98004 (US). TZANIS, Evangelos, L.; 3906 White Stone Road, Newtown Square, PA 19073 (US). GARRITY-RYAN, Lynne; 17 Laurel Street, Mel- rose, MA 02176 (US). MANLEY, Amy; 44 North Calder Way, Phoenixville, PA 19460 (US). Agent: HANLEY, Elizabeth, A. et al.; McCarter & Eng- lish, LLP, 265 Franklin Street, Boston, MA 02110 (US). (74) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) — Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = (84) 1-1 IN GC C:N (54) Title: 9-AMINOMETHYL MINOCYCLINE COMPOUNDS AND USES THEREOF SO 0 \" (57) : Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embod- ----. anent, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an GC effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein 1-1 © the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive N days, then at a dose of about 300 mg per day for 5 or more days. C